HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CROHN'S DISEASE: POSITION PAPER FROM THE TRANSPLANTATION COMMITTEE OF THE...

Area of Science:

• Gastroenterology and Immunology
• Cell Therapy and Transplantation

Background:

• Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease with complex immune dysregulation.
• Current treatments including anti-inflammatories, corticosteroids, immunosuppressants, and biologics often fail to provide a cure, leading to refractory disease.
• Over 80% of CD patients undergo surgery within ten years, highlighting the limitations of existing therapies.

Purpose of the Study:

• To review the history and outcomes of hematopoietic stem cell transplantation (HSCT) for Crohn's disease.
• To discuss the relevant aspects of HSCT and cell therapy in managing refractory CD.
• To provide an expert committee's perspective on this emerging treatment modality.

Main Methods:

• Review of existing literature and clinical reports on HSCT for Crohn's disease.
• Analysis of historical data and results from early studies.
• Expert committee discussion and synthesis of findings.

Main Results:

• Clinical remission has been observed in CD patients undergoing HSCT, particularly those with co-existing hematological malignancies.
• HSCT emerged as a potential alternative therapy for CD since 2010.
• The procedure's relevance and challenges in the context of CD management are detailed.

Conclusions:

• Hematopoietic stem cell transplantation represents a promising therapeutic avenue for refractory Crohn's disease.
• Further research and standardized protocols are needed to optimize HSCT outcomes in CD.
• Cell therapy holds potential for patients with limited treatment options.